Related Experiment Video
Updated: Apr 8, 2026
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?
Aspasia Soultati1, Mark Stares, Charles Swanton
1aGuys and St Thomas NHS Foundation Trust bThe Francis Crick Institute, 44 Lincoln's Inn Fields, London cUCL Cancer Institute, CRUK Lung Cancer Centre of Excellence, Huntley Street dRenal Unit, The Royal Marsden Hospital, London, UK.
Purpose Of Review:
Despite the availability of multiple targeted therapies, the 5-year survival rate of patients with metastatic clear cell renal cell carcinoma (ccRCC) rarely exceeds 10%. Recent insights into the mutational landscape and evolutionary dynamics of ccRCC have offered up a plausible explanation for these outcomes. The purpose of this review is to link the research findings to potential changes in clinical practice.
Recent Findings:
Intratumour heterogeneity (ITH) dominates the evolutionary landscape in ccRCC at the genetic, transcriptomic and proteomic level. Spatial and temporal separation of tumour subclones within the primary tumour as well as between primary and metastatic sites has been demonstrated at single nucleotide resolution. In the cases analysed to date, approximately two-thirds of somatic mutations are not shared between multiple biopsies from the same primary tumour. Very few of the key disease-driving events are shared across all primary tumour regions (with the exception of VHL and loss of chromosome 3p), whereas the majority are restricted to one or more tumour regions (TP53, SETD2, BAP1, PTEN, mTOR, PIK3CA and KDM5C).
Summary:
ITH must be considered in the management of ccRCC with respect to diagnostic procedures, prognostic and predictive biomarkers and drug development.
Insights
Intratumour heterogeneity (ITH) drives clear cell renal cell carcinoma (ccRCC) evolution. Understanding this complexity is crucial for improving ccRCC diagnosis, prognosis, and treatment strategies.
Area of Science:
- Oncology
- Genetics
- Cancer Biology
Background:
- Metastatic clear cell renal cell carcinoma (ccRCC) has a poor 5-year survival rate, often below 10%, despite targeted therapies.
- Recent research highlights the role of tumour evolution and mutational landscape in ccRCC outcomes.
Purpose of the Study:
- To connect current research findings on ccRCC evolutionary dynamics to potential clinical practice modifications.
- To emphasize the impact of intratumour heterogeneity (ITH) on ccRCC management.
Main Methods:
- Review of recent research on the genetic, transcriptomic, and proteomic landscape of ccRCC.
- Analysis of spatial and temporal tumour subclone separation at single nucleotide resolution.
- Examination of shared and unique somatic mutations across primary tumour regions and metastatic sites.
Main Results:
- Intratumour heterogeneity (ITH) is a dominant feature in ccRCC evolution across multiple molecular levels.
- Significant spatial and temporal divergence of tumour subclones exists within primary tumours and between primary and metastatic sites.
- Approximately two-thirds of somatic mutations are not shared across multiple biopsies of the same primary ccRCC, with most key driver events being region-specific (e.g., TP53, SETD2, BAP1).
Conclusions:
- Intratumour heterogeneity (ITH) must be integrated into the clinical management of ccRCC.
- Consideration of ITH is essential for refining diagnostic procedures, prognostic/predictive biomarkers, and novel drug development strategies for ccRCC.
